


NEUROMetrix®

NeuroMetrix, Inc.
Investor Relations Department
1000 Winter St. Attn: Accounts Payable
Attn: Accounts Payable
Waltham, MA 02451
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: NURO

Last Trade:	1.85
Trade Time:	4:00 PM ET Nov 22, 2017
Change:	-0.03  (-1.333%)
Day Range	1.72 - 2.15
52-Week Range	1.58 - 9.60
Volume	823,131

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most commo... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 31, 2017*
[NeuroMetrix Closes \\$3.5 Million Equity Offering](#)
- Oct 19, 2017*
[NeuroMetrix Reports Q3 2017 Financial Results](#)
- Oct 10, 2017*
[NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Results Conference Call](#)
- Sep 5, 2017*
[NeuroMetrix Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12th, 2017](#)
- Aug 31, 2017*
[Two Studies Derived from Quell Health Cloud to be Presented at Upcoming PAINWeek National Conference](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Feb 9, 2017*
[Annual Report \(10-K\)](#)
- Aug 7, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Oct 20, 2017*
[Quarterly Report \(10-Q\)](#)
- Jul 20, 2017*
[Quarterly Report \(10-Q\)](#)
- Apr 20, 2017*
[Quarterly Report \(10-Q\)](#)